nach oben

Erschienen in:

11.09.2023

New Developments in Image-Guided Percutaneous Irreversible Electroporation of Solid Tumors

verfasst von: Jung H. Yun, Adam Fang, Fereshteh Khorshidi, Peiman Habibollahi, Oleksandra Kutsenko, Vahid Etezadi, Stephen Hunt, Nariman Nezami

Erschienen in: Current Oncology Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review will describe the various applications, benefits, risks, and approaches of conventional irreversible electroporation (IRE), as well as highlight the new technological developments of this procedure along with their clinical applications.

Recent Findings

Minimally invasive image-guided percutaneous IRE ablation has emerged as a newer, non-thermal ablation technique for tumors in the solid organs, particularly within the liver, pancreas, kidney, and prostate. IRE allows for ablation near heat-sensitive structures, including major blood vessels and nerves, and is not susceptible to the heat sink effect. However, it is limited by certain requirements, such as the need for precise parallel placement of at least two probes with a maximum inter-probe distance of 2.5 cm to reduce the risk of arching phenomenon, the requirement for general anesthesia with muscle relaxant, and the need for cardiac synchronization. However, new technological advancements in the ablation system and image guidance tools have been introduced to improve the efficiency and efficacy of IRE.

Summary

IRE is a safe and effective treatment option for solid tumor ablation within the liver, pancreas, kidney, and prostate. Compared with other ablation techniques, IRE has several advantages, such as the absence of heat sink effect and minimal injury to blood vessels and bile ducts while activating the immune system. Novel techniques such as H-FIRE, needle placement systems, and robotics have enhanced the accuracy and performance in placement of IRE probes. IRE can be especially beneficial when combined with chemotherapy, immunomodulation, and immunotherapy.

Ruarus AH, Vroomen LGPH, Puijk RS, Scheffer HJ, Zonderhuis BM, Kazemier G, van den Tol MP, Berger FH, Meijerink MR. Irreversible Electroporation in Hepatopancreaticobiliary Tumours. Can Assoc Radiol J. 2018;69(1):38–50. https://doi.org/10.1016/j.carj.2017.10.005.CrossRefPubMed

Zhang N, Li Z, Han X, Zhu Z, Li Z, Zhao Y, Liu Z, Lv Y. Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors. Front Immunol. 2022;12:811726. https://doi.org/10.3389/fimmu.2021.811726.CrossRefPubMed

Narayanan G. Irreversible Electroporation. Semin Intervent Radiol. 2015;32(4):349–55. https://doi.org/10.1055/s-0035-1564706.CrossRefPubMedPubMedCentral

Fuhrmann I, Probst U, Wiggermann P, Beyer L. Navigation Systems for Treatment Planning and Execution of Percutaneous Irreversible Electroporation. Technol Cancer Res Treat. 2018;17:1533033818791792. https://doi.org/10.1177/1533033818791792.CrossRefPubMedPubMedCentral

Zhou L, Yin S, Chai W, Zhao Q, Tian G, Xu D, Jiang T. Irreversible electroporation in patients with liver tumours: treated-area patterns with contrast-enhanced ultrasound. World J Surg Oncol. 2020;18(1):305. https://doi.org/10.1186/s12957-020-02083-4.CrossRefPubMedPubMedCentral

Arena CB, Sano MB, Rossmeisl JH Jr, Caldwell JL, Garcia PA, Rylander MN, Davalos RV. High-frequency irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction. Biomed Eng Online. 2011;10:102. https://doi.org/10.1186/1475-925X-10-102.CrossRefPubMedPubMedCentral

Al-Sakere B, André F, Bernat C, Connault E, Opolon P, Davalos RV, Rubinsky B, Mir LM. Tumor ablation with irreversible electroporation. PloS One. 2007;2(11):e1135. https://doi.org/10.1371/journal.pone.0001135.CrossRefPubMedPubMedCentral

Thomson KR, Kavnoudias H, Neal RE 2nd. Introduction to Irreversible Electroporation—Principles and Techniques. Tech Vasc Interv Radiol. 2015;18(3):128–34. https://doi.org/10.1053/j.tvir.2015.06.002.CrossRefPubMed

Timmer FEF, Geboers B, Ruarus AH, Schouten EAC, Nieuwenhuizen S, Puijk RS, de Vries JJJ, Meijerink MR, Scheffer HJ. Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Tech Vasc Interv Radiol. 2020;23(2):100675. https://doi.org/10.1016/j.tvir.2020.100675.CrossRefPubMed

10.

Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48. https://doi.org/10.1177/153303460700600106.CrossRefPubMed

11.

Zimmerman A, Grand D, Charpentier KP. Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017;4:49–58.CrossRefPubMedPubMedCentral

12.

Bhutiani N, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RCG. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB. 2016;18(7):593–399. https://doi.org/10.1016/j.hpb.2016.03.609.CrossRefPubMedPubMedCentral

13.

Scheffer HJ, Vroomen LG, Nielsen K, van Tilborg AA, Comans EF, van Kuijk C, van der Meijs BB, van den Bergh J, van den Tol PM, Meijerink MR. Colorectal liver metastatic disease: efficacy of irreversible electroporation—a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer. 2015;15:772. https://doi.org/10.1186/s12885-015-1736-5.CrossRefPubMedPubMedCentral

14.

Alnaggar M, Qaid AM, Chen J, Niu L, Xu K. Irreversible electroporation of malignant liver tumors: Effect on laboratory values. Oncol Lett. 2018;16(3):3881–8. https://doi.org/10.3892/ol.2018.9058.CrossRefPubMedPubMedCentral

15.

Franken LC, van Veldhuisen E, Ruarus AH, Coelen RJS, Roos E, van Delden OM, Besselink MG, Klümpen HJ, van Lienden KP, van Gulik TM, Meijerink MR, Erdmann JI. Outcomes of Irreversible Electroporation for Perihilar Cholangiocarcinoma: A Prospective Pilot Study. J Vasc Interv Radiol. 2022;33(7):805-813.e1. https://doi.org/10.1016/j.jvir.2022.03.024.CrossRefPubMed

16.

Peng H, Shen J, Long X, Zhou X, Zhang J, Xu X, Huang T, Xu H, Sun S, Li C, Lei P, Wu H, Zhao J. Local Release of TGF-β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Immunotherapy. Adv Sci (Weinh). 2022;9(10):e2105240. https://doi.org/10.1002/advs.202105240.CrossRefPubMed

17.

Wah TM, Lenton J, Smith J, Bassett P, Jagdev S, Ralph C, Vasudev N, Bhattarai S, Kimuli M, Cartledge J. Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience. Eur Radiol. 2021;31(10):7491–9. https://doi.org/10.1007/s00330-021-07846-5.CrossRefPubMedPubMedCentral

18.

Wang Z, Lu J, Huang W, et al. A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety. BMC Cancer. 2021;21:124. https://doi.org/10.1186/s12885-021-07820-w.CrossRefPubMedPubMedCentral

19.

Ng H, Wang K, Cartledge J, et al. Ureteric Injury after Image-Guided Ablation of Renal Cell Cancer with Irreversible Electroporation. JVIR. 2020;32(2):P322-324. https://doi.org/10.1016/j.jvir.2020.09.015.CrossRef

20.

Wang H, Xue W, Yan W, et al. Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial. JAMA Surg. 2022;157(8):693–700. https://doi.org/10.1001/jamasurg.2022.2230.CrossRefPubMedPubMedCentral

21.

Geboers B, Scheffer HJ, Graybill PM, Ruarus AH, Nieuwenhuizen S, Puijk RS, van den Tol PM, Davalos RV, Rubinsky B, de Gruijl TD, Miklavčič D, Meijerink MR. High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. Radiology. 2020;295(2):254–72. https://doi.org/10.1148/radiol.2020192190.CrossRefPubMed

22.

Galvanize Therapeutics, Inc. Aliya System. https://galvanizetx.com/aliya-system. Accessed 20 June 2023.

23.

Endovascular Today. Galvanize Therapeutics’ Aliya PEF System Studied in Solid Tumors. https://evtoday.com/news/galvanize-therapeutics-aliya-pef-system-studied-in-solid-tumors. Accessed 20 June 2023.

24.

Beyer LP, Pregler B, Michalik K, Niessen C, Dollinger M, Müller M, Schlitt HJ, Stroszczynski C, Wiggermann P. Evaluation of a robotic system for irreversible electroporation (IRE) of malignant liver tumors: initial results. Int J Comput Assist Radiol Surg. 2017;12(5):803–9. https://doi.org/10.1007/s11548-016-1485-1.CrossRefPubMed

25.

de Baere T, Roux C, Noel G, Delpla A, Deschamps F, Varin E, Tselikas L. Robotic assistance for percutaneous needle insertion in the kidney: preclinical proof on a swine animal model. Eur Radiol Exp. 2022;6(1):13. https://doi.org/10.1186/s41747-022-00265-1.

26.

Guiu B, De Baère T, Noel G, et al. Feasibility, safety and accuracy of a CT-guided robotic assistance for percutaneous needle placement in a swine liver model. Sci Rep. 2021;11:5218. https://doi.org/10.1038/s41598-021-84878-3.CrossRefPubMedPubMedCentral

27.

Epione. Quantum Surgical. https://www.quantumsurgical.com/epione/ [Accessed 25 June 2023].

28.

de Baère T, Roux C, Deschamps F, Tselikas L, Guiu B. Evaluation of a New CT-Guided Robotic System for Percutaneous Needle Insertion for Thermal Ablation of Liver Tumors: A Prospective Pilot Study. Cardiovasc Intervent Radiol. 2022;45(11):1701–9. https://doi.org/10.1007/s00270-022-03267-z.CrossRefPubMedPubMedCentral

29.

Sun S, Liu Y, He C, Hu W, Liu W, Huang X, et al. Combining NanoKnife With M1 Oncolytic Virus Enhances Anticancer Activity in Pancreatic Cancer. Cancer Lett. 2021;502:9–24. https://doi.org/10.1016/j.canlet.2020.12.018.CrossRefPubMed

30.

Qian J, Chen T, Wu Q, Zhou L, Zhou W, Wu L, et al. Blocking Exposed PD-L1 Elicited by Nanosecond Pulsed Electric Field Reverses Dysfunction of CD8 T Cells in Liver Cancer. Cancer Lett. 2020;495:1–11. https://doi.org/10.1016/j.canlet.2020.09.015.CrossRefPubMed

31.

Burbach BJ, O’Flanagan SD, Shao Q, Young KM, Slaughter JR, Rollins MR, Street TJL, Granger VE, Beura LK, Azarin SM, Ramadhyani S, Forsyth BR, Bischof JC, Shimizu Y. Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells. Nat Commun. 2021;12(1):3862. https://doi.org/10.1038/s41467-021-24132-6.CrossRefPubMedPubMedCentral

Titel: New Developments in Image-Guided Percutaneous Irreversible Electroporation of Solid Tumors
verfasst von: Jung H. Yun
Adam Fang
Fereshteh Khorshidi
Peiman Habibollahi
Oleksandra Kutsenko
Vahid Etezadi
Stephen Hunt
Nariman Nezami
Publikationsdatum: 11.09.2023
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 11/2023
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01452-y

Springer Medizin

New Developments in Image-Guided Percutaneous Irreversible Electroporation of Solid Tumors